Huawei intends to sign more AI partnerships with pharmaceutical companies, according to William Zhang, president of its healthcare business unit, who told Reuters the projects currently run mainly with domestic Chinese drugmakers.
The company sells compound screening tools alongside its Ascend and Kunpeng chips, the same domestic stack it has been building out since US sanctions forced it to find workarounds.
“As we further deepen our research into AI in the medical field, we’ll have more collaboration and results emerging with pharmaceutical companies from drug manufacturing to clinical to final implementation,” Zhang said.
He also described existing collaborations in clinical practice in hospitals without elaborating on which ones.
There is no target number attached to any of this, and no prospective partner was named. It is a statement of direction rather than an announcement, which is worth establishing before the figures that will inevitably get attached to it start circulating.
